Takeda and Millennium's recent out-sized tie-up reflects the different but real industry pressures from which both companies are suffering.Facing near-term patent exiprations of several key drugs, Takeda desperately needed to bulk up its R&D pipeline. Millennium, for its own part, was heavily dependent on the label expansion of its lead product, Velcade, as it struggled to maintain sustainable earnings growth and advance its early stage compounds through the clinic.
On April 10, Takeda Pharmaceutical Co. Ltd. announced it had agreed to acquire
Cambridge-based Takeda Oncology for $25 a share in an all-cash deal worth
roughly $8.2 billion. [See Deal] If the deal terms remain the
same, Millennium will make its exit with the eighth highest market
value in the biotech industry, almost twice as much as the next
ones in line, Cephalon Inc., ImClone Systems Inc., and Vertex Pharmaceuticals Inc. That’s not bad for a company
with just one marketed product and fewer than a dozen promising,
but still risky, clinical assets.
Details of the deal were still emerging as IN VIVO went to press, but the out-sized price for the tie-up...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.